The effects of Aflibercept and Ranibizumab in patients with wet-type age-related macula degeneration

Basit Öğe Kaydı
dc.contributor.authorVural, Selahattin
dc.contributor.authorAva, Sedat
dc.contributor.authorPolat, Ferhat Baver
dc.contributor.authorKeklikci, Ugur
dc.date.accessioned2025-02-22T14:08:41Z
dc.date.available2025-02-22T14:08:41Z
dc.date.issued2025
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and objective: This study aims to compare the effects of two different anti-VEGF drugs, aflibercept and ranibizumab, on OCT findings in patients with AMD. Materials and methods: We reviewed the medical records of patients diagnosed with wet type AMD between 2013-2020, who were treated with intravitreal ranibizumab or aflibercept, and had a minimum follow-up period of six months. Results: Aflibercept was injected into 50 eyes and ranibizumab was injected into 53 eyes. In best corrected visual acuity (BCVA) measurements, aflibercept was found to be superior especially at 1 month (p=0.003), and no difference was found in BCVA at 6 months (p=0.233). A negative correlation was found between BCVA measurements and SFC measurements at 1 month (r=-0.322, p=0.001). In the comparison of aflibercept and ranibizumab at 6 months; Aflibercept was found to be more effective than ranibizumab in reducing CFT (p=0.014). However, no statistically significant difference was found between aflibercept and ranibizumab in horizontal PED, vertical PED, HRD, IRC, SRF, ERM, ELM, ISOS, and CNVM measurements (p=0.119; p=0.220; p=0.167; p=0.531; p=0.351; p=0.844; p=0.768; p=0.944; p=0.703, respectively). Conclusions: Intravitreal aflibercept and ranibizumab injections in wet AMD patients were found to have similar effects on other OCT findings except for CFT. Studies with long follow-up and large series on this subject will provide more information.en_US
dc.identifier.doi10.3306/AJHS.2025.40.01.40
dc.identifier.issn1579-5853
dc.identifier.issn2255-0569
dc.identifier.issue1en_US
dc.identifier.urihttps://doi.org/10.3306/AJHS.2025.40.01.40
dc.identifier.urihttps://hdl.handle.net/11468/29575
dc.identifier.volume40en_US
dc.identifier.wosWOS:001397896000005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherReial Acad Medicina Illes Balearsen_US
dc.relation.ispartofMedicina Balearen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectAge-related macular degenerationen_US
dc.subjectoptical coherence tomographyen_US
dc.subjectaflibercepten_US
dc.subjectranibizumaben_US
dc.subjectchoroidal neovascular membraneen_US
dc.subjectAge-related macular degenerationen_US
dc.subjectoptical coherence tomographyen_US
dc.subjectaflibercepten_US
dc.subjectranibizumaben_US
dc.subjectchoroidal neovascular membraneen_US
dc.titleThe effects of Aflibercept and Ranibizumab in patients with wet-type age-related macula degenerationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu